查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1575499

酶抑制剂市场：按产品类型、应用、最终用户、抑制机制、治疗领域、分子类型、酶目标 - 2025-2030 年全球预测

Enzyme Inhibitor Market by Product Type, Application, End User, Inhibition Mechanism, Therapeutic Area, Molecule Type, Enzyme Target - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年酵素抑制剂市值为21.4亿美元，预计到2024年将达到22.5亿美元，复合年增长率为7.07%，到2030年将达到34.5亿美元。

酵素抑制剂是与酵素结合併降低其活性的分子，在多种药物应用中发挥重要作用，包括治疗癌症和心血管疾病等疾病。对酵素抑制剂的需求源自于它们调节生化途径并透过控制酵素活性产生治疗效果的能力。酵素抑制剂广泛应用于药物开发、农业和生化研究，主要最终用途领域为製药、农业和生物技术。酶抑制剂市场的成长主要是由研发活动的增加、需要先进治疗的慢性疾病数量的增加以及生物技术行业的大量投资所推动的。关键影响因素包括精准医学的进步、使用酵素抑制剂进行客製化治疗的基因组研究以及增强药物发现过程的高通量筛检和生物资讯学等强大的技术发展。潜在的商机在于对标靶治疗不断增长的需求、扩大新兴国家开拓的市场以及扩大农业和工业酶抑制剂等非传统应用的应用。然而，它们面临着限制和挑战，例如高昂的研发成本、严格的法律规范、潜在的副作用导致毒性以及来自替代疗法的竞争。业务成长可能会透过围绕具有更高选择性、效力和安全性的新型酶抑制剂製剂的创新，以及在药物发现中使用人工智慧和机器学习进行预测建模来实现。该市场是动态的，其特点是主要联盟和合併以促进研究和开发，以及不断努力解决未满足的医疗需求。儘管面临全球经济情势波动和关键药物专利到期的挑战，但基础设施和医疗改革快速进展的地区为业务扩张和战略投资提供了一个有希望的途径。因此，对新兴生物技术和个人化医疗的关注可以支持该领域的指数增长和永续性。

主要市场统计
基准年[2023] 21.4亿美元
预测年份 [2024] 22.5亿美元
预测年份 [2030] 34.5亿美元
复合年增长率（%） 7.07%

市场动态：快速发展的酶抑制剂市场的关键市场洞察

供需的动态交互作用正在改变酵素抑制剂市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 对治疗慢性病的标靶治疗的需求不断增长
    • 生物技术的快速进步导致新型酵素抑制剂的开发
    • 酵素相关疾病盛行率上升促使需要有效的抑制剂
    • 产业巨头加大医药研发投入
  • 市场限制因素
    • 製药公司正在将重点转向生技药品，而不是传统的酵素抑制剂。
    • 替代疗法的激烈竞争限制了酵素抑制剂市场的成长
  • 市场机会
    • 利用酵素抑制剂实现个人化医疗保健中的精准医疗方法
    • 将酵素抑制剂纳入联合治疗以提高多重抗药性癌症的治疗效果
    • 探索酶抑制剂在农业中的应用，以改善作物保护和产量永续性
  • 市场挑战
    • 管理供应链中断并确保酵素抑制剂生产的品质稳定
    • 解决酶抑制剂领域的扩充性问题以及特定治疗应用的可自订性

波特五力：驾驭酵素抑制剂市场的策略工具

波特的五力框架是了解酵素抑制剂市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解酵素抑制剂市场的外部影响

外部宏观环境因素在塑造酶抑制剂市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解酵素抑制剂市场的竞争状况

对酶抑制剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位基质酶抑制剂市场供应商绩效评估

FPNV定位矩阵是评估酵素抑制剂市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，以规划酶抑制剂市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对酶抑制剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对治疗慢性疾病的标靶治疗的需求增加
      • 透过生物技术的快速进步开发新的酶抑制剂
      • 酵素相关疾病盛行率的上升增加了对有效抑制剂的需求
      • 主要产业参与者加大医药研发投入
    • 抑制因素
      • 製药公司正在将重点转向生技药品而不是传统的酵素抑制剂
      • 替代疗法的激烈竞争限制了酵素抑制剂市场的成长
    • 机会
      • 在个人化医疗解决方案中利用酵素抑制剂进行精准医学方法
      • 将酵素抑制剂纳入联合治疗以改善多重抗药性癌症的治疗结果
      • 探索酵素抑制剂在农业中的应用，以改善作物保护和产量永续性
    • 任务
      • 管理供应链中断并确保酵素抑制剂生产品质稳定
      • 解决酶抑制剂领域特定治疗应用的可扩展性问题和可自订性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章酶抑制剂市场：依产品类型

  • 竞争性抑制剂
    • 不可逆抑制剂
    • 可逆抑制剂
  • 非竞争性抑制剂
    • 变构抑制剂
    • 混合抑制剂
  • 非竞争性抑制剂

第七章酶抑制剂市场：依应用分类

  • 农业
  • 生物催化剂
  • 药品
  • 研究和生物技术

第八章酶抑制剂市场：依最终用户分类

  • 学术研究所
  • 合约调查机构
  • 医院/诊所
  • 製药公司

第九章依抑制机制分類的酵素抑制剂市场

  • 共用抑制剂
  • 非共用抑制剂

第10章依治疗领域分類的酵素抑制剂市场

  • 心臟病学
    • 抗凝血物
    • 抗高血压药
  • 感染疾病
    • 抗菌剂
    • 抗真菌药物
    • 抗病毒药物
  • 神经病学
    • 抗忧郁症
    • 抗癫痫药
  • 肿瘤学
    • 化疗
    • 标靶治疗

第十一章按分子类型分類的酵素抑制剂市场

  • 聚合物抑制剂
  • 小分子抑制剂

第十二章酶抑制剂市场酶目标

  • 激酶
  • 磷酸酶
  • 聚合酵素
  • 蛋白酶

第十三章美洲酶抑制剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第14章亚太地区酵素抑制剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章 欧洲、中东和非洲酵素抑制剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0579

The Enzyme Inhibitor Market was valued at USD 2.14 billion in 2023, expected to reach USD 2.25 billion in 2024, and is projected to grow at a CAGR of 7.07%, to USD 3.45 billion by 2030.

Enzyme inhibitors are molecules that bind to enzymes and decrease their activity, serving critical roles in various pharmaceutical applications, including treating diseases such as cancer, cardiovascular diseases, and more. The necessity of enzyme inhibitors arises from their ability to regulate the biochemical pathways by controlling the activity of enzymes, providing therapeutic benefits. They are widely applied in drug development, agriculture, and biochemical research, with major end-use sectors being pharmaceuticals, agriculture, and biotechnology. The market growth for enzyme inhibitors is primarily driven by increasing R&D activities, the rise in chronic diseases necessitating advanced treatments, and substantial investments in biotechnology industries. Key influencing factors include advancements in precision medicine, genomic studies empowering tailored therapies using enzyme inhibitors, and robust technological developments like high-throughput screening and bioinformatics enhancing drug discovery processes. Potential opportunities prevail in the growing demand for targeted therapies, substantial untapped markets in emerging economies, and expanding applications for non-traditional uses such as agriculture and industrial enzyme inhibitors. However, the market faces limitations and challenges such as high R&D costs, stringent regulatory frameworks, potential side effects leading to toxicity, and competition from alternative therapies. Business growth could be capitalized by innovations concerning novel enzyme inhibitor formulations with higher selectivity, potency, and safety profiles, alongside leveraging AI and machine learning for predictive modeling in drug discovery. The market is dynamic, characterized by significant collaborations and mergers to foster R&D, with a continuous endeavor to address unmet medical needs. Fluctuating global economic conditions and patent expiration of key drugs can pose challenges, yet regions with burgeoning infrastructure and healthcare reforms indicate promising avenues for expansion and strategic investments. Thus, focusing on emerging biotechnologies and personalized medicine could underpin exponential growth and sustainability in this sector.

KEY MARKET STATISTICS
Base Year [2023] USD 2.14 billion
Estimated Year [2024] USD 2.25 billion
Forecast Year [2030] USD 3.45 billion
CAGR (%) 7.07%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Enzyme Inhibitor Market

The Enzyme Inhibitor Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for targeted therapies in the treatment of chronic diseases
    • Rapid advancements in biotechnology leading to novel enzyme inhibitors development
    • Rising prevalence of enzyme-related disorders driving the need for effective inhibitors
    • Growing investments in pharmaceutical research and development by major industry players
  • Market Restraints
    • Pharmaceutical companies shifting focus towards biologics over traditional enzyme inhibitors
    • Stiff competition from alternative treatments restraining the growth of enzyme inhibitor market
  • Market Opportunities
    • Leveraging enzyme inhibitors for precision medicine approaches in personalized healthcare solutions
    • Integration of enzyme inhibitors in combination therapies to enhance treatment outcomes for multi-drug resistance cancers
    • Exploration of enzyme inhibitors in agricultural applications to improve crop protection and yield sustainability
  • Market Challenges
    • Managing supply chain disruptions and ensuring consistent quality in enzyme inhibitor production
    • Addressing scalability issues and customizability for specific therapeutic applications in the enzyme inhibitor sector

Porter's Five Forces: A Strategic Tool for Navigating the Enzyme Inhibitor Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Enzyme Inhibitor Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Enzyme Inhibitor Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Enzyme Inhibitor Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Enzyme Inhibitor Market

A detailed market share analysis in the Enzyme Inhibitor Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Enzyme Inhibitor Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Enzyme Inhibitor Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Enzyme Inhibitor Market

A strategic analysis of the Enzyme Inhibitor Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Enzyme Inhibitor Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Enzyme Inhibitor Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Competitive Inhibitors, Non-Competitive Inhibitors, and Uncompetitive Inhibitors. The Competitive Inhibitors is further studied across Irreversible Inhibitors and Reversible Inhibitors. The Non-Competitive Inhibitors is further studied across Allosteric Inhibitors and Mixed Inhibitors.
  • Based on Application, market is studied across Agriculture, Biocatalysts, Pharmaceuticals, and Research & Biotechnology.
  • Based on End User, market is studied across Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical Companies.
  • Based on Inhibition Mechanism, market is studied across Covalent Inhibitors and Non-Covalent Inhibitors.
  • Based on Therapeutic Area, market is studied across Cardiology, Infectious Diseases, Neurology, and Oncology. The Cardiology is further studied across Anti-Coagulants and Anti-Hypertensives. The Infectious Diseases is further studied across Antibacterials, Antifungals, and Antivirals. The Neurology is further studied across Anti-Depressants and Anti-Epileptics. The Oncology is further studied across Chemotherapy and Targeted Therapy.
  • Based on Molecule Type, market is studied across Large Molecule Inhibitors and Small Molecule Inhibitors.
  • Based on Enzyme Target, market is studied across Kinases, Phosphatases, Polymerases, and Proteases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for targeted therapies in the treatment of chronic diseases
      • 5.1.1.2. Rapid advancements in biotechnology leading to novel enzyme inhibitors development
      • 5.1.1.3. Rising prevalence of enzyme-related disorders driving the need for effective inhibitors
      • 5.1.1.4. Growing investments in pharmaceutical research and development by major industry players
    • 5.1.2. Restraints
      • 5.1.2.1. Pharmaceutical companies shifting focus towards biologics over traditional enzyme inhibitors
      • 5.1.2.2. Stiff competition from alternative treatments restraining the growth of enzyme inhibitor market
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging enzyme inhibitors for precision medicine approaches in personalized healthcare solutions
      • 5.1.3.2. Integration of enzyme inhibitors in combination therapies to enhance treatment outcomes for multi-drug resistance cancers
      • 5.1.3.3. Exploration of enzyme inhibitors in agricultural applications to improve crop protection and yield sustainability
    • 5.1.4. Challenges
      • 5.1.4.1. Managing supply chain disruptions and ensuring consistent quality in enzyme inhibitor production
      • 5.1.4.2. Addressing scalability issues and customizability for specific therapeutic applications in the enzyme inhibitor sector
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Enzyme Inhibitor Market, by Product Type

  • 6.1. Introduction
  • 6.2. Competitive Inhibitors
    • 6.2.1. Irreversible Inhibitors
    • 6.2.2. Reversible Inhibitors
  • 6.3. Non-Competitive Inhibitors
    • 6.3.1. Allosteric Inhibitors
    • 6.3.2. Mixed Inhibitors
  • 6.4. Uncompetitive Inhibitors

7. Enzyme Inhibitor Market, by Application

  • 7.1. Introduction
  • 7.2. Agriculture
  • 7.3. Biocatalysts
  • 7.4. Pharmaceuticals
  • 7.5. Research & Biotechnology

8. Enzyme Inhibitor Market, by End User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Contract Research Organizations
  • 8.4. Hospitals & Clinics
  • 8.5. Pharmaceutical Companies

9. Enzyme Inhibitor Market, by Inhibition Mechanism

  • 9.1. Introduction
  • 9.2. Covalent Inhibitors
  • 9.3. Non-Covalent Inhibitors

10. Enzyme Inhibitor Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Cardiology
    • 10.2.1. Anti-Coagulants
    • 10.2.2. Anti-Hypertensives
  • 10.3. Infectious Diseases
    • 10.3.1. Antibacterials
    • 10.3.2. Antifungals
    • 10.3.3. Antivirals
  • 10.4. Neurology
    • 10.4.1. Anti-Depressants
    • 10.4.2. Anti-Epileptics
  • 10.5. Oncology
    • 10.5.1. Chemotherapy
    • 10.5.2. Targeted Therapy

11. Enzyme Inhibitor Market, by Molecule Type

  • 11.1. Introduction
  • 11.2. Large Molecule Inhibitors
  • 11.3. Small Molecule Inhibitors

12. Enzyme Inhibitor Market, by Enzyme Target

  • 12.1. Introduction
  • 12.2. Kinases
  • 12.3. Phosphatases
  • 12.4. Polymerases
  • 12.5. Proteases

13. Americas Enzyme Inhibitor Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Enzyme Inhibitor Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Enzyme Inhibitor Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Biogen Inc.
  • 7. Boehringer Ingelheim GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Novo Nordisk A/S
  • 16. Pfizer Inc.
  • 17. Regeneron Pharmaceuticals, Inc.
  • 18. Roche Holding AG
  • 19. Sanofi S.A.
  • 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ENZYME INHIBITOR MARKET RESEARCH PROCESS
  • FIGURE 2. ENZYME INHIBITOR MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENZYME INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ENZYME INHIBITOR MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. ENZYME INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENZYME INHIBITOR MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENZYME INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENZYME INHIBITOR MARKET DYNAMICS
  • TABLE 7. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY IRREVERSIBLE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY REVERSIBLE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY MIXED INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY UNCOMPETITIVE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY BIOCATALYSTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY RESEARCH & BIOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTI-COAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTI-HYPERTENSIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTIBACTERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY LARGE MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY KINASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PHOSPHATASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY POLYMERASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PROTEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. CHINA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. CHINA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. CHINA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. INDIA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. INDIA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. INDIA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. INDIA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 198. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. JAPAN ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 211. JAPAN ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. JAPAN ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 213. JAPAN ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. JAPAN ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 224. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 250. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 262. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 267. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 269. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 270. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 273. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 274. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 275. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 278. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 280. THAILAND ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. THAILAND ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 282. THAILAND ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 283. THAILAND ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. THAILAND ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. THAILAND ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 286. THAILAND ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 287. THAILAND ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. THAILAND ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 289. THAILAND ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 290. THAILAND ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 291. THAILAND ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. THAILAND ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 293. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 295. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 296. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 299. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 300. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 301. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 302. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 303. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 304. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 320. DENMARK ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. DENMARK ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 322. DENMARK ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 323. DENMARK ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. DENMARK ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 325. DENMARK ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 326. DENMARK ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 327. DENMARK ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 328. DENMARK ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 329. DENMARK ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 330. DENMARK ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 331. DENMARK ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. DENMARK ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 333. EGYPT ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 334. EGYPT ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 335. EGYPT ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 336. EGYPT ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 337. EGYPT ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 338. EGYPT ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 339. EGYPT ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 340. EGYPT ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 341. EGYPT ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 342. EGYPT ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 343. EGYPT ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 344. EGYPT ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 345. EGYPT ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 346. FINLAND ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. FINLAND ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)

TABLE